Bright Peak Presents New Data at AACR: BPT567 A First-in-Class Multifunctional PD1-IL18 Immunocytokine

SAN DIEGO and BASEL, Switzerland, April 17 (Korea Bizwire) — Bright Peak Therapeutics, a biotechnology company developing multifunctional precision immunotherapies for cancer and autoimmune disease, today announced the presentation of new data characterizing the highly targeted biological and therapeutic effects of BPT567 that contribute to its potent single agent anti-tumor activity at the American Association [...]

Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1 Targeted Immunocytokines at SITC 2022

SAN DIEGO and BASEL, Switzerland, Nov. 9 (Korea Bizwire) — Bright Peak Therapeutics, a privately held biotechnology company developing next-generation, multifunctional precision immunotherapies for cancer and autoimmune disease, today announced the presentation of multiple new cancer immunotherapy agents at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held on November [...]